Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$11.71 0.31 (2.72%)
2/9/2010 4:00 PM

Nektar Therapeutics (NKTR)

CAPS Rating:
***

A biopharmaceutical company which develops breakthrough products that make a difference in patients' lives. It creates differentiated, innovative products by applying its platform technologies to established or novel medicines.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating NKTR

Add Stock to Watchlist

What the Community Thinks

Total Members

160 Outperforms
25 Underperforms
 

All-Stars

41 Outperforms
11 Underperforms
 

Wall Street

7 Outperforms
1 Underperforms
 

Members bullish on NKTR are also bullish on:

Members bearish on NKTR are also bearish on:

Ticker Tags

Aggressive Growth (860), Life Sciences Tools and Services (53), Growth (1902), Small Cap (1645), Defensive (1457), Distressed (1597), Healthcare (711)
Suggest a tag

Nektar Therapeutics At A Glance

Current Price: $11.71
Last Trade Time: 2/9/2010 4:00 PM
Open: $11.56
Previous Close: $11.40
Daily Range: $11.40 - $11.76
52-Week Range: $4.00 - $12.28
Volume: 611,817
Market Cap: $1.09B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

NKTR VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

2

Nektar Therapeutics (NKTR)

Avatar TheBotttomFeeder (97.34) Submitted: 10/31/08 4:48 PM

I just noticed how outdated all of the pitches for and against NKTR are. The Exubera debacle is behind them, and people are just waking up to the notion that this is a different company with a bright future.

There are a lot of positives here: The burn rate has been cut. A recent partnership with B...More

Replies: 2 | Reply | Permalink

Top Bear Pitch

Recs

2

Nektar Therapeutics (NKTR)

Avatar honcharella (86.28) Submitted: 3/14/07 7:22 PM

This company just can't make a move upward. One of many with this type of technology and also one of many that just fails to produce results in the form of profits. Maybe one day... Just not today.

Replies: 1 | Reply | Permalink

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 42 :   1 2 3 4 5 Next »

Show Pitch Replies

Recs

0

 (NKTR)

Avatar CroMagnon1948 (54.55) Submitted: 2/01/10 9:46 AM : Outperform Start Price: $11.28 NKTR Score: 4.91

Superior institutional sponsorship, good chart, who knows?

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NKTR)

Avatar mrbill6 (< 20) Submitted: 1/21/10 8:23 AM : Outperform Start Price: $12.02 NKTR Score: 3.30

msn:10, navallier:B

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (NKTR)

Avatar 4everlost (94.97) Submitted: 4/28/09 3:44 PM : Underperform Start Price: $5.62 NKTR Score: -82.08

The stock price is up 33% over the last year in spite of these terrible #s:   Price/Cash Flow = -42.8   Rev. Gwth.
(Last vs. Prior TTM)= -67.0%   Profit Margin = -38.1%   Ret. on Invest. (TTM) = -7.4%   Current Ratio = 5.9
I expect they will use up the money in the bank and struggle to get more.   

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (NKTR)

Avatar TheBotttomFeeder (97.34) Submitted: 10/31/08 4:48 PM : Outperform Start Price: $3.65 NKTR Score: 224.11

I just noticed how outdated all of the pitches for and against NKTR are. The Exubera debacle is behind them, and people are just waking up to the notion that this is a different company with a bright future.

There are a lot of positives here: The burn rate has been cut. A recent partnership with Bayer for inhaled Amikacin had very favorable terms. The sale of the pulmonary arm of the company minus some of the most advanced candidates to NVS strengthened NKTR's financial position, and cost them little. Perhaps most importantly, the power and value of their PEGylation platform is just now starting to get some of the attention it deserves. NKTR-102, NKTR-105, NKTR-118, NKTR-119. These are the proprietary drug candidates that could make anybody buying NKTR in the current price range a very happy camper in 3-5 years. NKTR-102, PEG irinotecan, is already showing convincing signs of substantial improvement over the unmodified parent molecule. This combined with the revenue stream expected from the partnered products makes NKTR an extremely undervalued company that few have noticed in the wreckage of the larger market.

Report this Post Replies: 2 | Reply | Permalink

Recs

0

 (NKTR)

Avatar b3agle (< 20) Submitted: 5/19/08 12:48 PM : Outperform Start Price: $4.58 NKTR Score: 178.41

Turn around already!

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 42 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 8 of 8  

picks per page. CHANGE

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackWedbush 66.12 12/07/09 Outperform NS $9.76+19.98%-3.05%+23.03
TrackBMOCapital 91.22 09/23/09 Outperform NS $10.15+15.37%+0.13%+15.24
TrackBreanMurray 86.47 06/23/09 Outperform NS $6.23+87.96%+20.41%+67.56
TrackWMBlair 69.55 04/07/09 Outperform NS $5.10+129.61%+31.71%+97.89
TrackMorganJos < 20 03/24/09 Outperform NS $4.94+137.04%+33.35%+103.69
TrackOppenheimer 81.36 03/01/07 Outperform NS $11.86-1.26%-19.25%+17.99
TrackDeutscheSec 89.68 03/01/07 Outperform NS $11.72-0.09%-19.12%+19.03
TrackJimCramer < 20 08/03/06 Underperform 3W $16.54-29.20%-10.38%+18.82

Results 1 - 8 of 8  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 640ms